Moonlake Immunotherapeutics Begins Phase 3 VELA Program Of The Nanobody Sonelokimab In Patients With Moderate-To-Severe Hidradenitis Suppurativa; Topline Primary Endpoint Readout At Week 16, Together With Data On Other Endpoints, Is Expected As Of Mid-2025

MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa

• VELA is the first Phase 3 program in hidradenitis suppurativa to use the higher clinical response level of HiSCR75 as the primary endpoint
• The topline primary endpoint readout at week 16, together with data on other endpoints, is expected as of mid-2025
  • Program will evaluate sonelokimab for a total of 52 weeks, across VELA-1 and VELA-2, at sites in the United States and Europe, using a design informed by the landmark Phase 2 MIRA trial